236 related articles for article (PubMed ID: 28945273)
21. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation.
St Hilaire RC; Murthy SN; Kadowitz PJ; Jeter JR
Peptides; 2010 Aug; 31(8):1517-22. PubMed ID: 20452385
[TBL] [Abstract][Full Text] [Related]
22. Radical reversal of vasoactive intestinal peptide (VIP) receptors during early lymphopoiesis.
Vomhof-DeKrey EE; Sandy AR; Failing JJ; Hermann RJ; Hoselton SA; Schuh JM; Weldon AJ; Payne KJ; Dorsam GP
Peptides; 2011 Oct; 32(10):2058-66. PubMed ID: 21878358
[TBL] [Abstract][Full Text] [Related]
23. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
24. VPAC Receptor Subtypes Tune Purinergic Neuron-to-Glia Communication in the Murine Submucosal Plexus.
Fung C; Boesmans W; Cirillo C; Foong JPP; Bornstein JC; Vanden Berghe P
Front Cell Neurosci; 2017; 11():118. PubMed ID: 28487635
[TBL] [Abstract][Full Text] [Related]
25. Mismatch novelty exploration training shifts VPAC
Aidil-Carvalho F; Caulino-Rocha A; Ribeiro JA; Cunha-Reis D
J Neurosci Res; 2024 Apr; 102(4):e25333. PubMed ID: 38656542
[TBL] [Abstract][Full Text] [Related]
26. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis.
Sun W; Hong J; Zang YC; Liu X; Zhang JZ
Int Immunol; 2006 Dec; 18(12):1691-700. PubMed ID: 17077178
[TBL] [Abstract][Full Text] [Related]
27. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells.
Lara-Marquez M; O'Dorisio M; O'Dorisio T; Shah M; Karacay B
J Immunol; 2001 Feb; 166(4):2522-30. PubMed ID: 11160313
[TBL] [Abstract][Full Text] [Related]
28. The neurotransmitter VIP expands the pool of symmetrically dividing postnatal dentate gyrus precursors via VPAC2 receptors or directs them toward a neuronal fate via VPAC1 receptors.
Zaben M; Sheward WJ; Shtaya A; Abbosh C; Harmar AJ; Pringle AK; Gray WP
Stem Cells; 2009 Oct; 27(10):2539-51. PubMed ID: 19650041
[TBL] [Abstract][Full Text] [Related]
29. Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors.
Nicol MR; Cobb VJ; Williams BC; Morley SD; Walker SW; Mason JI
J Mol Endocrinol; 2004 Jun; 32(3):869-77. PubMed ID: 15171718
[TBL] [Abstract][Full Text] [Related]
30. VPAC2 receptor mediates VIP-potentiated insulin secretion via ion channels in rat pancreatic β cells.
Zhao X; Deng L; Ren L; Yang H; Wang B; Zhu X; Zhang X; Guo C; Zhang Y; Liu Y
Exp Cell Res; 2023 Feb; 423(2):113471. PubMed ID: 36642263
[TBL] [Abstract][Full Text] [Related]
31. The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy.
Dickinson T; Mitchell R; Robberecht P; Fleetwood-Walker SM
Neuropharmacology; 1999 Jan; 38(1):167-80. PubMed ID: 10193908
[TBL] [Abstract][Full Text] [Related]
32. Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity.
Seoane IV; Ortiz AM; Piris L; Lamana A; Juarranz Y; García-Vicuña R; González-Álvaro I; Gomariz RP; Martínez C
PLoS One; 2016; 11(2):e0149141. PubMed ID: 26881970
[TBL] [Abstract][Full Text] [Related]
33. Activation of Th lymphocytes alters pattern expression and cellular location of VIP receptors in healthy donors and early arthritis patients.
Villanueva-Romero R; Gutiérrez-Cañas I; Carrión M; González-Álvaro I; Rodríguez-Frade JM; Mellado M; Martínez C; Gomariz RP; Juarranz Y
Sci Rep; 2019 May; 9(1):7383. PubMed ID: 31089161
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation of vasoactive intestinal peptide and altered expression of its receptors in rat diabetic cardiomyopathy.
Dvoráková MC; Pfeil U; Kuncová J; Svíglerová J; Galvis G; Krasteva G; König P; Grau V; Slavíková J; Kummer W
Cell Tissue Res; 2006 Mar; 323(3):383-93. PubMed ID: 16344947
[TBL] [Abstract][Full Text] [Related]
35. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes.
Tsutsumi M; Claus TH; Liang Y; Li Y; Yang L; Zhu J; Dela Cruz F; Peng X; Chen H; Yung SL; Hamren S; Livingston JN; Pan CQ
Diabetes; 2002 May; 51(5):1453-60. PubMed ID: 11978642
[TBL] [Abstract][Full Text] [Related]
36. Postweaning Development Influences Endogenous VPAC
Gil M; Caulino-Rocha A; Bento M; Rodrigues NC; Silva-Cruz A; Ribeiro JA; Cunha-Reis D
Biomolecules; 2024 Mar; 14(3):. PubMed ID: 38540797
[TBL] [Abstract][Full Text] [Related]
37. Atypical nuclear localization of VIP receptors in glioma cell lines and patients.
Barbarin A; Séité P; Godet J; Bensalma S; Muller JM; Chadéneau C
Biochem Biophys Res Commun; 2014 Nov; 454(4):524-30. PubMed ID: 25450687
[TBL] [Abstract][Full Text] [Related]
38. Vasoactive intestinal peptide and its receptors in human ovarian cortical follicles.
Gabbay-Benziv R; Ao A; Fisch B; Zhang L; Oron G; Kessler-Icekson G; Ben-Haroush A; Krissi H; Abir R
PLoS One; 2012; 7(5):e37015. PubMed ID: 22623971
[TBL] [Abstract][Full Text] [Related]
39. Effect of VIP on intracellular [Ca2+], extracellular regulated kinase 1/2, and secretion in cultured rat conjunctival goblet cells.
Li D; Jiao J; Shatos MA; Hodges RR; Dartt DA
Invest Ophthalmol Vis Sci; 2013 Apr; 54(4):2872-84. PubMed ID: 23518767
[TBL] [Abstract][Full Text] [Related]
40. VIP protects human retinal microvascular endothelial cells against high glucose-induced increases in TNF-α and enhances RvD1.
Shi H; Carion TW; Jiang Y; Steinle JJ; Berger EA
Prostaglandins Other Lipid Mediat; 2016 Mar; 123():28-32. PubMed ID: 27026343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
